Home › Triple-Negative Breast Cancer › Texas › Irving
Triple-Negative Breast Cancer clinical trials in Irving, TX
4 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Irving (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- NEXT Oncology - Irving, Irving
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- NEXT Oncology - Dallas, Irving
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
RecruitingPhase 1
- Next Oncology Dallas /ID# 276254, Irving
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
RecruitingPhase 1
- NEXT Texas LLC - Dallas, Irving
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN27 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO20 studies
- Arlington, VA20 studies
- Atlanta, GA19 studies
- Dallas, TX18 studies
- Columbus, OH16 studies
- Chicago, IL16 studies
Other studies in Irving
- Non-Small Cell Lung Cancer22 studies
- Cancer (all types)15 studies
- Colorectal Cancer13 studies
- Metastatic Cancer11 studies
- Pancreatic Cancer7 studies
- Stomach Cancer7 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Lung Cancer6 studies
- Small Cell Lung Cancer6 studies
- Breast Cancer6 studies
- Ovarian Cancer5 studies
- Esophageal Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.